CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 159 enrolled
Drug / intervention
A-101 Topical Solution +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03278028
NCT03278028Phase 2Completed
CompareCT.gov

A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Twice a Week in Subjects With Common Warts

Aclaris Therapeutics, Inc.·interventional·Posted Sep 11, 2017·Updated Apr 9, 2019

In Brief

A Phase 2 clinical trial evaluating A-101 Topical Solution and A-101 Vehicle Solution for Common Wart. Completed, enrolled 159 participants across 16 sites.

Detailed Summary

The primary objective of this study is to evaluate the effectiveness of A-101 compared to Vehicle when applied to 1 Target common wart on the trunk or extremities twice a week.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCommon Wart
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedSep 11, 2017
Enrollment StartJul 13, 2017
Primary CompletionMar 1, 2018
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 8.8 years ago

Interventions

A-101 Topical Solutiondrug

A-101 Topical Solution

A-101 Vehicle Solutiondrug

A-101 Vehicle Solution